This invention relates to the use of flurbiprofen and ibuprofen, their pharmaceutically acceptable salts and esters in a method of increasing bone mass and the treatment and prevention of bone mass loss excepting alveolar bone mass loss or increase. More particularly this invention relates to the treatment of osteoporosis by administering flurbiprofen or ibuprofen, their salts or esters.

The invention relates to a process for the production of a tablet containing S-ibuprofen which rapidly releases the active compound, and to S-ibuprofen-containing tablets prepared by this process.

The product consists of tablets which contain at least 600 mg of ibuprofen and a binder, or a mixture of binders, based on cellulose and cellulose derivatives in the form of microspheres which are coated with an acrylic resin of defined nature and are compressed together with a disintegrant; the tablets are preferably also coated with a lacquer layer. As a consequence of the high content of active compound and its delayed release in the body, the therapeutic treatment with ibuprofen can be reduc...

Provided herein are compositions and methods of making compositions of ibuprofen in combination with a narcotic analgesic. Specifically provided is a pharmaceutical tablet composition comprising ibuprofen; a narcotic analgesic; colloidal silicon dioxide; a filler selected from the group consisting of microcrystalline cellulose and powdered cellulose; a disintegrant selected from the group consisting of croscarmellose sodium, crospovidone, and sodium starch glycolate; a binder consisting of an ak...

Novel treatments are disclosed for increasing circulating coronary blood flow. These treatments are useful for individuals who are expected to otherwise exhibit symptoms of reduced coronary circulation. Such individuals include those having coronary artery disease, angina, particularly unstable angina and Prinzmetal's angina, and coronary vasospasm. In accordance with the disclosed methods, coronary vasodilation is accomplished through the administration of effective amounts of buiprofen and/or ...

A pharmaceutical composition includes a core of an NSAID selected from ibuprofen and ibuprofen salts, which core is surrounded by an intermediate coating impermeable to the passage of ibuprofen and a mantle coating which includes a prostaglandin surrounding the coated ibuprofen core.

Direct compressible ibuprofen particles are formed by treating commercially available, dry ibuprofen with a hydrophilic solvent in one embodiment, a mixture of a hydrophilic solvent and one or more hydrophobic organic solvents in a second embodiment and one or more hydrophobic organic solvents in a third embodiment, to change at least the external crystalline shape of the ibuprofen from a flow-retarding shape to a free-flowing, easily compressible configuration. A typical hydrophilic solvent is ...

This invention pertains to a method of purifying ibuprofen-comprising reaction product mixtures. The method of purification is based on crystallization of ibuprofen from a hydrocarbon solvent and the discovery that there are impurity complexes in the ibuprofen-comprising reaction product mixtures which cannot be removed by crystallization from a hydrocarbon solvent. The method of the invention includes at least one step in which the impurity complex in a first ibuprofen-comprising mixture is des...

A medicament for immediately treating painful, inflammatory and/or febrile diseases contains as active substance ibuprofen as a racemate, as a racemic mixture with its enantiomers, as a pseudoracemate (mixtures of equal parts of S- and R-ibuprofen) or as a mixture of different parts of S- and R-ibuprofen in a range between pure S- and pure R-ibuprofen in the form of a pharmaceutically applicable nanosol and satisfies all requirements of an immediate-effect pharmaceutic form. It can in addition b...

In particular, the invention relates to a new, clearly dissolving ibuprofen effervescent formulation and a process for the preparation of this formulation. Ibuprofen or (.+-.)2-(4-isobutylphenyl)-propionic acid has the following structural formula ##STR1## and has been for years a proven, non-steroidal antiphlogistic from the group of phenylpropionic acid derivatives, which shows effectiveness in veterinary experimental inflammation models by inhibiting prostaglandin synthesis.